Clinical Research & Patient Care Core (CRPCC)

临床研究

基本信息

项目摘要

IN-TRAC Clinical Research & Patient Care Core (CRPCC) ABSTRACT Tuberculosis (TB) is a leading infectious disease cause of death worldwide. In the US, TB incidence rates are historically low, but control remains challenging in certain populations, including the communities along the US border with Mexico. Thus, there is an urgent need for the next generation of TB researchers to have an understanding of the clinical and epidemiological aspects of TB research, as a foundation for their future leadership in the development of improved TB diagnostics, surveillance, treatments and vaccines. The Clinical Research & Patient Care Core (CRPCC) of the IN-TRAC will provide to New TB Investigators (NIs) and investigators new to the TB field, the infrastructure, resources and training in TB clinical research, and education on the challenges faced by clinicians in managing TB cases. Our training sites are strategically located in south Texas, a state adjacent to Mexico, which is the number one country of origin for foreign-born TB cases in the US. The TB clinical research site is led by Dr. Restrepo, an expert in TB field epidemiology and pathogenesis in TB patients with diabetes comorbidity or old age. Her field site is unique within the US due to its access to TB patients enrolled on the Mexican side of the Texas border. The TB patient care training will be in San Antonio, led by Drs. Armitige and Seaworth, an exemplary team of physicians who are affiliated with the only free-standing TB hospital in the US, the Texas Center for Infectious Diseases (TCID). In the same setting, there are also busy outpatient clinics: The San Antonio Metropolitan Health Department Chest Clinic, and a TB regional training and medical consultation Center of Excellence (The Heartland National TB Center; HNTBC). Our Aims are to: Aim 1. Execute a personalized training curriculum on TB clinical research studies. We have designed a hybrid (hands-on and virtual) training curriculum for IN-TRAC participants on all aspects of Clinical TB Research, including ethics, study design, field logistics, data and specimen management, specimen processing and data analysis plans and communications. Aim 2. Execute a personalized training curriculum on TB patient care. IN-TRAC participants will be educated on the complex set of decisions that physicians make, particularly during the management of difficult TB cases (e.g. with DR-TB, or with social problems such as homelessness), and who require specialized management and prolonged in-hospital stays. The mentoring team will meet with each IN-TRAC participant prior to their rotation to discuss customization of the core curriculum, including the development of a pilot project, depending on the IN-TRAC participant’s interest. IN-TRAC participants will provide a written and oral evaluation of their training experience.
TRAC临床研究与患者护理核心(CRPCC)摘要 结核病(TB)是全球主要的传染病死亡原因。在美国,结核病发病率是 历史上的低水平,但在某些人群中,控制仍然具有挑战性,包括美国沿线的社区 与墨西哥接壤。因此,迫切需要下一代结核病研究人员拥有一种 了解结核病研究的临床和流行病学方面,作为其未来的基础 在改进的结核病诊断、监测、治疗和疫苗的开发方面发挥领导作用。《临床》 TRAC的研究和患者护理核心(CRPCC)将为新的结核病调查人员(NIS)和 结核病领域的新研究人员,结核病临床研究和教育方面的基础设施、资源和培训 关于临床医生在管理结核病病例方面面临的挑战。我们的培训地点位于南部,地理位置优越。 得克萨斯州,一个毗邻墨西哥的州,是世界上最大的外国出生结核病病例的来源地 我们。结核病临床研究网站由雷斯特雷波博士领导,他是结核病现场流行病学和发病机制方面的专家 肺结核合并糖尿病或老年患者。她的现场站点在美国是独一无二的,因为它可以接触到结核病 患者在德克萨斯州边境的墨西哥一侧登记。结核病患者护理培训将在圣安东尼奥举行, 由Armitige博士和Seaworth博士领导的一个模范医生团队隶属于唯一独立的 美国德克萨斯州传染病中心(TCID)的结核病医院。在同样的环境中,也有忙碌的 门诊诊所:圣安东尼奥大都会卫生局胸科诊所,以及结核病区域培训和 卓越医疗咨询中心(哈特兰国家结核病中心;HNTBC)。我们的目标是:瞄准 1.实施结核病临床研究的个性化培训课程。我们设计了一种混合动力车 (动手和虚拟)为TRAC参与者提供临床结核病研究各方面的培训课程, 包括伦理、研究设计、现场后勤、数据和标本管理、标本处理和数据 分析计划和沟通。目标2.实施关于结核病患者护理的个性化培训课程。 TRAC参与者将接受有关医生做出的一系列复杂决定的培训,特别是在 管理疑难结核病病例(如耐药结核病或无家可归等社会问题);以及 他们需要专门的管理和长时间的住院。 指导团队将在轮换之前与每位TRAC参与者会面,讨论定制 核心课程,包括开发一个试点项目,这取决于《核心预算资源调拨目标》参与者的兴趣。 核心预算资源调拨目标内参与者将提供对其培训经验的书面和口头评估。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Larry S. Schlesinger其他文献

Mycobacterium tuberculosis remodels host transcriptome
结核分枝杆菌重塑宿主转录组
  • DOI:
    10.1038/s41564-021-01056-x
  • 发表时间:
    2022-01-31
  • 期刊:
  • 影响因子:
    19.400
  • 作者:
    Melanie A. Carless;Larry S. Schlesinger
  • 通讯作者:
    Larry S. Schlesinger
Identifying Mycobacterium tuberculosis virulence determinants - new technologies for a difficult problem.
识别结核分枝杆菌毒力决定因素——解决难题的新技术。
  • DOI:
  • 发表时间:
    2000
  • 期刊:
  • 影响因子:
    15.9
  • 作者:
    Lucy E. Desjardin;Larry S. Schlesinger
  • 通讯作者:
    Larry S. Schlesinger
Antibody-independent classical complement pathway activation by wildtype and LPS O-antigen mutant <em>Francisella tularensis</em> strains
  • DOI:
    10.1016/j.molimm.2010.05.146
  • 发表时间:
    2010-08-01
  • 期刊:
  • 影响因子:
  • 作者:
    Corey D. Clay;John S. Gunn;Larry S. Schlesinger
  • 通讯作者:
    Larry S. Schlesinger
Timing matters in macrophage/CD4+ T cell interactions: an agent-based model comparing emMycobacterium tuberculosis/em host-pathogen interactions between latently infected and naïve individuals
时机在巨噬细胞/CD4+T 细胞相互作用中很重要:一个基于代理的模型比较了潜伏感染和未感染个体之间的结核分枝杆菌宿主-病原体相互作用
  • DOI:
    10.1128/msystems.01290-24
  • 发表时间:
    2025-02-27
  • 期刊:
  • 影响因子:
    4.600
  • 作者:
    Alexis Hoerter;Alexa Petrucciani;Jordan Bonifacio;Eusondia Arnett;Larry S. Schlesinger;Elsje Pienaar
  • 通讯作者:
    Elsje Pienaar
Impact of the elderly lung mucosa on emMycobacterium tuberculosis/em transcriptional adaptation during infection of alveolar epithelial cells
老年肺黏膜对肺泡上皮细胞感染期间结核分枝杆菌转录适应性的影响
  • DOI:
    10.1128/spectrum.01790-24
  • 发表时间:
    2024-10-30
  • 期刊:
  • 影响因子:
    3.800
  • 作者:
    Angélica M. Olmo-Fontánez;Anna Allué-Guardia;Andreu Garcia-Vilanova;Jeremy Glenn;Shu-Hua Wang;Robert E. Merritt;Larry S. Schlesinger;Joanne Turner;Yufeng Wang;Jordi B. Torrelles
  • 通讯作者:
    Jordi B. Torrelles

Larry S. Schlesinger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Larry S. Schlesinger', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10431466
  • 财政年份:
    2022
  • 资助金额:
    $ 12.83万
  • 项目类别:
Interdisciplinary NexGen TB research Advancement Center (IN-TRAC)
跨学科 NexGen 结核病研究推进中心 (IN-TRAC)
  • 批准号:
    10588203
  • 财政年份:
    2022
  • 资助金额:
    $ 12.83万
  • 项目类别:
Clinical Research & Patient Care Core (CRPCC)
临床研究
  • 批准号:
    10431471
  • 财政年份:
    2022
  • 资助金额:
    $ 12.83万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10588204
  • 财政年份:
    2022
  • 资助金额:
    $ 12.83万
  • 项目类别:
Interdisciplinary NexGen TB research Advancement Center (IN-TRAC)
跨学科 NexGen 结核病研究推进中心 (IN-TRAC)
  • 批准号:
    10431465
  • 财政年份:
    2022
  • 资助金额:
    $ 12.83万
  • 项目类别:
Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection
健康和结核分枝杆菌感染期间的巨噬细胞核受体、代谢和免疫效应器
  • 批准号:
    10450960
  • 财政年份:
    2020
  • 资助金额:
    $ 12.83万
  • 项目类别:
Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection
健康和结核分枝杆菌感染期间的巨噬细胞核受体、代谢和免疫效应器
  • 批准号:
    10457308
  • 财政年份:
    2019
  • 资助金额:
    $ 12.83万
  • 项目类别:
Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection- Diversity Supplement
健康和结核分枝杆菌感染期间的巨噬细胞核受体、代谢和免疫效应器 - Diversity Supplement
  • 批准号:
    10116937
  • 财政年份:
    2019
  • 资助金额:
    $ 12.83万
  • 项目类别:
Expansion of Marmoset Breeding Facilities to Meet Increasing Research Demands
扩建狨猴饲养设施以满足不断增长的研究需求
  • 批准号:
    9933536
  • 财政年份:
    2019
  • 资助金额:
    $ 12.83万
  • 项目类别:
Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection
健康和结核分枝杆菌感染期间的巨噬细胞核受体、代谢和免疫效应器
  • 批准号:
    10215474
  • 财政年份:
    2019
  • 资助金额:
    $ 12.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了